The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Open accessAbstract
BACKGROUND: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. OBJECTIVE: The aim was to determine the impact of dupilumab on infection rates in patients with moderate-to-severe AD. METHODS: This analysis pooled data from seven randomized, placebo-controlled dupilumab trials in adults with moderate-to-severe AD. Exposure-adjusted analyses assessed infection rates. RESULTS: Of 2932 patients, 1091 received placebo, 1095 dupilumab 300 mg weekly, and 746 dupilumab 300 mg every 2 weeks. Treatment groups had similar infection rates overall per 100 patient-years (placebo, 155; dupilumab weekly, 150; dupilumab every 2 weeks, 156; dupilumab combined, 152), and similar non-skin infection rates. Serious/severe infections were reduced with dupilumab (risk ratio 0.43; p < 0.05), as were bacterial and other non-herpetic skin infections (risk ratio 0.44; p < 0.001). Although herpesviral infection rates overall were slightly higher with dupilumab than placebo, clinically important herpesviral infections (eczema herpeticum, herpes zoster) were less common with dupilumab (risk ratio 0.31; p < 0.01). Systemic anti-infective medication use was lower with dupilumab. CONCLUSIONS: Dupilumab is associated with reduced risk of serious/severe infections and non-herpetic skin infections and does not increase overall infection rates versus placebo in patients with moderate-to-severe AD. CLINICALTRIALS. GOV IDENTIFIERS: NCT01548404, NCT02210780, NCT01859988, NCT02277743, NCT02277769, NCT02260986, and NCT02755649.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citationConjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Self-citationSignificance of Skin Barrier Dysfunction in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. M. (2018) · Allergy, Asthma & Immunology Research · doi:10.4168/aair.2018.10.3.207 · Cited by 393
Cited by
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
Self-citationPaller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.054 · Cited by 399
Self-citationPaller, A. S., Simpson, E. L., Siegfried, E. C., Cork, M. J., Wollenberg, A., Arkwright, P. D., Soong, W., Gonzalez, M. E., Schneider, L. C., Sidbury, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01539-2 · Cited by 281
Self-citationBieber, T., Thyssen, J. P., Reich, K., Simpson, E. L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16948 · Cited by 152
Self-citation
Metadata
- Authors
- Eichenfield, L. F., Bieber, T., Beck, L. A., Simpson, E. L., Thaçi, D., de Bruin-Weller, M., Deleuran, M., Silverberg, J. I., Ferrandiz, C., Fölster-Holst, R., Chen, Z., Graham, N. M. H., Pirozzi, G., Akinlade, B., Yancopoulos, G. D., & Ardeleanu, M.
- Venue
- American Journal of Clinical Dermatology
- Published
- 2019-05-07
- Volume
- 20
- Issue
- 3
- Pages
- 443-456
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- OpenAlex
- W2944522746
- Cited by
- 184
- References
- 6
- FWCI
- 22.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. https://app.cochat.ai/papers/10.1007/s40257-019-00445-7
- The paper
- Eichenfield, L. F., Bieber, T., Beck, L. A., Simpson, E. L., Thaçi, D., de Bruin-Weller, M., Deleuran, M., Silverberg, J. I., Ferrandiz, C., Fölster-Holst, R., Chen, Z., Graham, N. M. H., Pirozzi, G., Akinlade, B., Yancopoulos, G. D., & Ardeleanu, M. (2019). Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-019-00445-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.